Belite Bio’s Tinlarebant positive phase III result for Stargardt disease
December 2, 2025

Belite Bio’s Tinlarebant Delivers Positive Phase III Results for Stargardt Disease

A rare win in Stargardt research breathes fire into a field long stuck in slow motion.  In a field where…

Mental health support for patients with vision loss
November 21, 2025

Seeing Beyond Vision Loss: Integrating Mental Health Into Retinal Care

Where retinal care meets real talk on the mind behind the macula.  In a field where innovation often takes center…

latest posts
Belite Bio’s Tinlarebant positive phase III result for Stargardt disease
December 2, 2025

Belite Bio’s Tinlarebant Delivers Positive Phase III Results for Stargardt Disease

Mental health support for patients with vision loss
November 21, 2025

Seeing Beyond Vision Loss: Integrating Mental Health Into Retinal Care

Illustration of two hands holding two puzzle pieces with the first hands holding a blue one and on the top of the hand is the logo of Eli Lilly, the other hand is holding a yellow puzzle and under it is the MeiraGTx logo with a pink background
November 11, 2025

Eli Lilly Expands Gene Therapy Portfolio to Eye Care with $475M MeiraGTx Deal

chiesi idebenone_thumbnail
September 23, 2025

FDA Grants Priority Review to Idebenone for Leber Hereditary Optic Neuropathy

Euretina_Session_10
September 7, 2025

From Rare to Repair: Inherited Retinal Disease Therapies Advance at Speed

thumb day 4
September 7, 2025

Connecting the Retina Dots: EVICR.net x EURETINA 2025

Nanoscope strengthens_thumbnail
September 4, 2025

Nanoscope Secures Major Global Wins for MCO-010 with EMA and FDA Designations

first patients treated in jCyte_Thumbnail
August 20, 2025

First Patients Dosed in jCyte’s Phase II JC02-88 Trial for Retinitis Pigmentosa

Discover our fascinating content at issuu

explore